BC
JAZZ icon

Bayforest Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bayforest Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-291
Closed -$55K – 1081
2026
Q1 		$55K Sell
291
-1,159
-80% -$203K 0.06% 534
2025
Q4 		$247K Sell
1,450
-280
-16% -$42.9K 0.18% 216
2025
Q3 		$228K Sell
1,730
-4,061
-70% -$487K 0.11% 354
2025
Q2 		$615K Buy
5,791
+3,996
+223% +$434K 0.27% 122
2025
Q1 		$223K Buy
+1,795
New +$234K 0.1% 369

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Bayforest Capital's JAZZ Position: Q2 2026 in Review

Bayforest Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 291 shares — an estimated $55K sold.

Bayforest Capital first reported a position in JAZZ in Q1 2025 and held it in 5 quarters. The position peaked at $615K in Q2 2025. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Bayforest Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bayforest Capital sold 291 Jazz Pharmaceuticals shares in Q2 2026, an estimated $55K.
  • Bayforest Capital first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Bayforest Capital's Jazz Pharmaceuticals position peaked at $615K in Q2 2025.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.